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Abstract The fibronectin promoter contains an ATF/cyclic
AMP (cAMP) response element (CRE) site two helical turns
upstream of a CCAAT site with which it interacts. We
investigated the effects of mutating these 3170 CRE and
3150 CCAAT elements on the promoter activity regulated by
three different modulators previously known to act through
CRE: ATF-2, cAMP and E1a. While the cooperation seems to
play no role in E1a action, integrity of the 3150 CCAAT is
necessary for ATF-2 and cAMP efficient activation in a cell-
specific manner. These results show that the CRE and CCAAT
elements function as a ‘composite element’ and establish a cell-
specific function for CRE-CCAAT synergy.
z 1999 Federation of European Biochemical Societies.
Key words: Cyclic AMP response element-CCAAT
cooperation; Cyclic AMP; ATF-2; E1a; Fibronectin
1. Introduction
Gene expression patterns in mammalian cells depend on the
precise action of the transcription and splicing machineries.
How the many DNA and RNA regulatory signals direct the
timely assembly of the appropriate multiprotein complexes
has been the subject of extensive research, although no general
principles have emerged. The ¢bronectin (FN) gene o¡ers a
suitable model to study the multimolecular processes that reg-
ulate transcription and splicing [1]. It is transcribed at di¡er-
ent levels from a single promoter in all tissues and gives rise to
tissue-speci¢c alternative splicing isoforms. FN has an essen-
tial role in development [2] and changes in its expression pat-
tern are involved in pathology, particularly of liver [3].
The FN gene promoter contains a TATA box and several
proximal regulatory sequences, including a canonical cyclic
AMP (cAMP) response element (AFT/CRE or simply CRE,
5P TGACGTCA 3P) at position 3170. The factors that bind
to the CRE site belong to a diversi¢ed family of leucine zipper
transcriptional activators collectively known as ATF factors
[4]. Some of them are preferentially activated by a particular
signaling pathway, but as they all bind DNA with the same
sequence-speci¢city, it remains unknown how they are specif-
ically recruited to a given promoter. Interactions with other
transcription factors are likely to contribute to their pro-
moter-speci¢city.
The FN 3170 CRE appears to be involved in di¡erent
regulations of the promoter. Besides mediating cAMP stimu-
lation in certain cell types [5,6], this element is essential for
responsiveness to serum [7] and to the adenovirus E1a onco-
protein [8]. We have previously shown that the occupation of
the 3170 CRE site in vitro in liver extracts depends on the
presence and appropriate positioning of the neighboring 3150
CCAAT site, located exactly two helical turns away [9]. In this
system, we showed that the FN-CRE factor that cooperates
with CCAAT-binding in liver contains an ATF-2 subunit [10].
ATF-2 is a ubiquitous transcription factor containing a basic
region leucine zipper motif that interacts with transcriptional
activators that lack sequence-speci¢c DNA-binding activities
like the retinoblastoma protein (Rb) [11] and viral activators
such as adenovirus E1a [12] and HTLV-1 Tax [13]. Phospho-
rylation of ATF-2 by the c-Jun NH2-terminal protein kinase
has been shown to modify three ATF-2-mediated transcrip-
tional activations: induction by serum and trans-activations
by Rb and E1a [14]. The central role of ATF-2 is evidenced by
the severe abnormalities observed in ATF-2 knock-out mice
[15].
We have previously shown that disruption of both the 3170
CRE and 3150 CCAAT sites was detrimental for the in vivo
activity of the FN promoter and non-additive (i.e. synergistic)
with respect to the single mutations [16]. Given the complexity
of the signal transduction through the FN 3170 CRE site, we
investigate here the importance of the cooperation in regu-
lated transcription by three di¡erent modulators previously
known to act through the CRE: ATF-2, cAMP and E1a.
While the cooperation seems to play no role in E1a action,
integrity of the 3150 CCAAT is essential for ATF-2 and
cAMP activation in a cell-speci¢c manner. In the absence of
the CCAAT site, speci¢city is lost. These results confer the
CRE and CCAAT elements the category of a ‘composite el-
ement’ and establish a cell-speci¢c function for CRE-CCAAT
synergy, providing a novel framework to understand the basis
for the speci¢c activity of distinct ATF/CRE sites [17,18].
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2. Materials and methods
2.1. Plasmids
2.1.1. FN promoter mutants. A USB site-directed mutagenesis kit
was used to introduce disruptive mutations in p-220-FN-CAT (re-
ferred to as ‘the wild-type (wt)’). This plasmid contains a 3223/+44
BstNI fragment of the human FN promoter cloned into the HindIII
site of pSV0CAT [19]. The 3170 wtCRE 5P GTGACGTCAC 3P site
was mutated to 5P ATGGCTTCAC 3P. The 3150 wtCCAAT 5P
GCCAATC 3P was mutated to 5P GCCCCTC 3P. Three chloramphe-
nicol acetyl transferase (CAT) expressing mutants were prepared:
p-220-FNmutCRE-CAT (referred to as ‘the mutant CRE (mutCRE)’),
p-220-FNCCccT-CAT (referred to as ‘the CCccT mutant’) and p-220-
FNdouble-CAT (referred to as ‘the double mutant’). p-125-FN-CAT
was obtained by deleting the 217 bp EagI fragment from p-220-FN-
CAT. Construction of p-500-FN-CAT was described previously [20].
2.1.2. Other expression plasmids. pMT-C-K, kindly provided by
Daniel Altschuler, expresses the K-isoform of the protein kinase A
catalytic subunit under the control of the human metallothionein pro-
moter. pRSVLgal expresses bacterial L-galactosidase under the control
of the Rous sarcoma virus long terminal repeat (LTR). pSV2CAT [19]
produces chloramphenicol acetyl transferases from the SV40 early
promoter. The 13S and 12S alternative splicing variants of the adeno-
viral protein E1a were expressed form plasmids pCMV13SE1a and
pCMV12SE1a, respectively (kind gifts of Roberto Weinman), both
controlled by the human cytomegalovirus immediate early promoter.
pCEV-ATF-2, a kind gift of Silvio Gutkind, has the full length human
ATF-2 cDNA under the control of the Moloney murine leukemia
virus LTR. To obtain a plasmid expressing ATF-2 antisense RNA,
named pCEV-2FTA, pCEV-ATF-2 was cut with XhoI and re-ligated,
in order to allow for an inversion of the 1.5 kpb cDNA insert with
respect to the promoter.
2.2. Cell cultures and transfections
The human hepatoma cell lines Hep3B and HepG2 were cultured in
DMEM (low glucose) (Life Technologies, Bethesda, MD, USA) sup-
plemented with 10% fetal bovine serum. NIH3T3 and HT1080 cells
were cultured in high glucose DMEM. In all experiments, cells were
transfected in 10 cm plates by the calcium phosphate method [19] and
harvested and lysed 48 h after washing of DNA. Cell extracts were
used to measure L-galactosidase and CAT activities as described [20].
Equal amounts of L-galactosidase activity were used in each CAT
assay.
3. Results
3.1. CRE-CCAAT synergy and ATF-2
We have previously reported that the cooperation between
the 3170 CRE and 3150 CCAAT sites detected in vitro [9,10]
is also relevant for the basal activity of the FN promoter in
vivo [16]. This cooperative e¡ect correlated with the in vitro
interaction between the CRE-binding factor AFT-2 and the
CCAAT factors NF-I and CP1 [16]. However, we had no
evidence of the in vivo role of ATF-2 on the FN promoter
activity. To investigate it, we chose two strategies: (i) over-
expression of human ATF-2 and (ii) expression of antisense
human ATF-2 RNA. Overexpression of ATF-2 by transient
Fig. 1. E¡ect of the expression of ATF-2 antisense RNA on the wt and CRE/CCAAT mutant FN promoters in di¡erent cell lines. A: Hep3B
(lanes 1 and 2), HepG2 (lanes 3^6) or NIH3T3 (lanes 7 and 8) cells were transfected with 10 Wg of p-220-FN-CAT (lanes 1^4, 7 and 8) or
SV40-CAT (lanes 5 and 6) constructs. Lanes 2, 4, 6 and 8 correspond to co-transfections with 5 Wg of pCEV-2FTA, a plasmid expressing anti-
sense ATF-2 RNA. Lane 3^6, each lane is a set of transfection duplicates. B: 10 Wg of wt (lanes 1 and 2) or CRE/CCAAT mutant (lanes 3^6)
was transfected in HepG2 cells. Lanes 2, 4 and 6 show co-transfections with 5 Wg of pCEV-2FTA. Schematic diagrams of wt and mutant con-
structs are shown at the bottom of each set of duplicates of transfection. In all experiments, transfection e⁄ciencies were determined by co-
transfection with 10 Wg of pRSVLgal. Relative CAT activities (R.A.) are referred to the wt. CAT assays are shown in duplicates of transfection.
Bars represent the average+S.D. of transfection triplicates.
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expression of its cDNA under the control of the Moloney
murine leukemia virus LTR has no e¡ect on the transcrip-
tional activity of p-220-FN-CAT in hepatic cells, but stimu-
lates by 3-fold the same promoter in non-hepatic cells (data
not shown). Consistently, expression of the antisense con-
struct, named pCEV-2FTA, inhibits transcription driven by
p-220-FN-CAT in Hep3B (Fig. 1A, lanes 1 and 2) and
HepG2 cells (lanes 3 and 4), but not in NIH3T3 cells (lanes
Fig. 2. E¡ect of cAMP-dependent protein kinase (PKA) activation of the wt and mutant promoters in Hep3B (A and B) and non-hepatic (C)
cells. A: CAT assays of transfections with 10 Wg of p-220-FN-CAT (lanes 1 and 2) and CRE/CCAAT mutants (lanes 3^8). Lanes 2, 4, 6 and 8
correspond to co-transfections with 5 Wg of pMT-CK, a plasmid encoding the catalytic subunit of PKA. B: Transfections with 10 Wg of wt
(lanes 1^4) and p-125-FN-CAT (lanes 5^9). Lanes 3, 4, 7 and 8 correspond to co-transfections with 5 Wg of pMT-CK. Each lane is a set of du-
plicates of transfection. C: NIH3T3 cells were transfected with 10 Wg of wt (lanes 1 and 2) and CRE/CCAAT mutants (lanes 3^8). Lanes 2, 4,
6 and 8 correspond to co-transfections with 5 Wg of plasmid pMT-CK. Each lane is a single transfection but quanti¢cation bars correspond to
duplicates. Heights of quanti¢cation bars correspond to the average of each duplicate value, indicated by a dot. Other conditions and diagrams
are as in Fig. 1.
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7 and 8). As promoter-speci¢city controls, CAT activity of
pSV2CAT (lanes 5 and 6) or pCMV-CAT (not shown) trans-
fected into HepG2 cells is not inhibited by 2FTA.
Fig. 1B shows that the inhibitory e¡ect of 2FTA over the
wt FN promoter brings down transcriptional activity to a
minimal level similar to the e¡ects of CRE disruption (lanes
1^3). The inhibitory e¡ect of the antisense is speci¢c on the
ATF/CRE element, since expression of the mutCRE construct
itself is not a¡ected by 2FTA (compare lanes 3 and 4). How-
ever, and most strikingly, activity of the CCccT mutant, that
harbors an unaltered CRE, is much less inhibited by 2FTA
(a 30% reduction) than the wt promoter (85%) (lanes 5 and
6).
3.2. CRE-CCAAT synergy and cAMP
To test if the 3170 CRE mediated cAMP activation in
hepatic cells, we studied the e¡ect of overexpression of the
catalytic subunit of protein kinase A (C-PKA) on the tran-
scriptional activity of the p-220-FN-CAT constructs. Fig. 2A
shows that in Hep3B cells, C-PKA activates the wt FN pro-
Fig. 3. E¡ect of the expression of two E1a alternative splicing variants on the wt and double CRE/CCAAT mutant FN promoters. A: Hep3B
cells were transfected with 10 Wg of wt (lanes 1^3) or double mutant (lanes 4 and 5). Co-tranfections with pCMV13SE1a (lanes 2 and 5) or
pCMVE1a12S (lanes 3) are indicated. B: Experiment identical to A, but in HepG2 cells. Only quanti¢cations are shown. C: NIH3T3 cells
transfected with p-220-FN-CAT (lanes 1^5) or pSV2CAT (lanes 6 and 7) and co-transfected with pCMV13SE1a (lanes 2^4 and 7) or
pCMVE1a12S (lanes 5). The amounts of E1a expressing plasmids in the transfections are: 0.2 Wg (lane 2), 1.0 Wg (lane 3) and 5 Wg (lanes 4, 5
and 7).
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moter by about 4-fold (lane 2). Activation varies between 4-
and 11-fold in di¡erent experiments. Similar levels of activa-
tion were obtained by treating the cells with 10 mM forskolin
or 1 mM dibutyryl cAMP (not shown). CRE inactivation
signi¢cantly reduces the activity in the presence of C-PKA
(compare lanes 2 and 4). The same e¡ect is observed when
the CCAAT box is inactivated (compare lanes 2 and 6) or
with the double mutant (compare lanes 2 and 8). The fact
that the CCccT mutation inhibits the ability of the 3170
CRE to respond to C-PKA activation strongly supports
that the CRE-CCAAT interaction plays a key role in media-
ting cAMP induction in Hep3B cells.
In all three mutants, there is a remnant PKA-stimulated
activity. This is unlikely to be caused by residual binding of
transcription factors to the mutated DNA sites, as both gel
shift and DNAse I footprinting experiments showed that the
mutations abolish the binding of transcription factors to the
sites completely ([16] and data not shown). Alternatively, it
could be the consequence of cAMP activation through a site
downstream of 3170 CRE, presumably the AP-2 site located
at position 357. To test this hypothesis, a deletion construct
(p-125-FN-CAT) spanning from 3125 to +44 (lacking the
CRE-CCAAT region) was tested in response to C-PKA.
Fig. 2B shows that although p-125-FN-CAT displays a very
low basal activity, it is indeed greatly activated by C-PKA,
con¢rming the presence of a secondary induction site.
In NIH3T3 cells, cAMP activation does not require the
CCAAT box. Although CRE disruption greatly reduces
PKA activation (Fig. 2C), CCAAT disruption does not a¡ect
the response (compare lanes 6 and 2), indicating that CRE-
CCAAT cooperation is not essential for cAMP activation
in this cell type. A similar result was observed in HepG2
cells.
3.3. Dualistic e¡ect of E1a
A very well-characterized mechanism involving ATF-2 is
transactivation by the adenovirus factor E1a. E1a exists as
two alternative splicing variants: 13S and 12S. Only the 13S
variant is able to interact with ATF-2 through its CR3 trans-
activation domain, resulting in transcriptional activation of
promoters containing CRE/ATF sites [12]. To test the e¡ect
of E1a on the FN promoter in hepatic cells, we co-transfected
FN-CAT constructs with 13S cDNA under the control of the
human CMV promoter (pCMV13SE1a) in Hep3B cells. Fig.
3A shows that, contrary to expected, instead of activating,
13S E1a strongly inhibits the FN promoter (lane 2). The
same e¡ect is observed with the 12S variant (lane 3), indicat-
ing that this inhibition does not involve the CR3 domain.
Furthermore, the inhibitory e¡ect does not involve the CRE
site (nor its interaction with the CCAAT site) because both
single mutants (not shown) and the double mutant are inhib-
ited by overexpression of 13S E1a (compare lanes 1 and 2
with 4 and 5). Similar results were obtained in HepG2 cells
(Fig. 3B, only quanti¢cations are shown).
In NIH3T3 ¢broblasts, E1a activates the FN promoter
mainly through its CR3 domain (Fig. 3C). In fact, the 13S
variant increases the FN promoter activity by 5.5-fold (com-
pare lanes 1 and 4), while the 12S variant is less e¡ective (lane
5). This activation is CRE-speci¢c, since it is impaired when
the 3170 CRE is disrupted (not shown) and is promoter-spe-
ci¢c, as the SV40 promoter is una¡ected by E1a 13S (lanes 6
and 7).
4. Discussion
4.1. Signal transduction through the FN gene CRE site
The 3220/+44 region of the human FN promoter has all
the features of a typical promoter-proximal+core promoter
region [21], i.e. recognition sites for factors such as ATFs,
CCAAT-binding proteins, AP-2 and Sp1, located upstream
of a canonical TATA box at position 325. Several studies
have demonstrated or suggested the involvement of the
3170 CRE site in transcriptional activation in response to
cAMP, 13S E1a and ATF-2. This variety of activators pro-
vides an ideal framework to explore the needs for signaling-
speci¢city.
By the use of in vitro approaches, we have previously
studied the properties and participants of a synergistic coop-
eration between the 3170 CRE and 3150 CCAAT sites of the
FN promoter in rat liver nuclear extracts. This in vitro inter-
action involves protein-protein interactions between a CRE-
binding factor which contains at least one ATF-2 subunit [10]
and the CCAAT-binding factors NF-I and CP1 [16,9,10].
We assessed here the e¡ect of abolishing the binding of
transcription factors to either the CRE or CCAAT sites on
regulatory pathways that so far were supposed to be mediated
only by the CRE site: those of ATF-2, cAMP and E1a.
4.2. ATF-2
Overexpression of ATF-2 has no e¡ect on the FN promoter
in hepatic cells, but stimulates by 3-fold the same promoter in
NIH3T3 ¢broblasts (data not shown). Consistently, expres-
sion of the antisense ATF-2 RNA (2FTA) inhibits the FN
promoter in Hep3B and HepG2 cells, but not in NIH3T3 cells
(Fig. 1). A possible interpretation of this is that both Hep3B
and HepG2 cells have saturating levels of endogenous active
ATF-2, su⁄cient to maintain basal FN promoter activity,
which is therefore not a¡ected by overexpression of the factor,
but can be brought down by its corresponding antisense.
NIH3T3 cells seem to have limiting amounts of active ATF-
2 and are able to activate the exogenous one, making the FN
promoter responsive to overexpression of recombinant ATF-
2.
The inhibitory e¡ect of 2FTA on the wt FN promoter in
hepatic cells brings transcriptional activity down to low levels
similar to those of mutCRE. The simplest interpretation of
this result is that ATF-2 is a required component of the ATF
factor that binds to the CRE site and that in its absence, no
other ATF factors can activate transcription through this site.
This is surprising, considering that there are a variety of ATF
factors able to bind to the FN-CRE site. In our gel shift
experiments with extracts from liver [9,10] and the cell lines
studied here (not shown), several complexes form on the FN-
CRE probe and only one of them contains ATF-2. It seems
that something precludes the action of the other factors in
vivo. Alternatively, it might be that the antisense is having
an indirect e¡ect on the promoter by a¡ecting other genes.
We controlled for a general e¡ect on transcription, showing
that other promoters (SV40, CMV) are not inhibited. The fact
that the ATF-2 antisense does not have any e¡ect on the
CRE-disrupted promoter rules out a repression of the FN
promoter other than the depletion of the active CRE-binding
protein itself. We conclude that ATF-2 is directly required for
the activity of the 3170 CRE site. The result observed with
the CCccT mutation supports the idea of a selectivity for
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ATF-2 that is lost when the CCAAT site is mutated. We show
that expression of the ATF-2 antisense (Fig. 2B, lane 6) has
only a minor e¡ect on the activity of the CCccT mutant,
suggesting that in the absence of this site, other ATF factors,
besides ATF-2, must bind the CRE site and activate tran-
scription.
4.3. cAMP
Two regions mediate stimulation of the FN promoter by
the cAMP pathway (C-PKA experiments) in hepatic cells : the
3170 CRE-CCAAT region and a region located downstream
3125, presumably involving the 357 AP-2 site [5]. We tested
the requirement for each site and found that in HepG2,
Hep3B and NIH3T3, the 3170 CRE site is needed for the
response to cAMP. However, only in Hep3B cells, the propor-
tional part that depends on the CRE-CCAAT region is de-
pendent on the integrity of both elements. Disruption of either
the CRE or the CCAAT site results in complete loss of signal-
ing through that region, equivalent to simultaneous inactiva-
tion of both sites.
In previous reports, the activity of the FN 3170 CRE site
has been shown to depend on the promoter context. When
this site was transplanted upstream of a non-responsive thy-
midine kinase promoter, it conferred cAMP activation to the
chimera in HT1080 ¢broblasts. However, the same element
was shown to be dispensable for the cAMP activation of
the proximal 500 bp of the human FN promoter in the
same cells [22]. We have con¢rmed this by showing that the
3220 FN promoter is completely unresponsive to cAMP in
HT1080 cells (CGP and ARK, unpublished observations).
This is in good agreement with our ¢nding that context-de-
pendent interactions are required for proper functioning of
the 3170 CRE site. Similar observations with respect to
the need of a CCAAT box for cAMP action were reported
in the rat arylalkylamine N-acetylatransferase gene promoter
[23].
4.4. E1a
The antisense and overexpression experiments indicate that
under basal conditions, ATF-2 is already in an active form in
the hepatomas Hep3B and HepG2, but is inactive or less
abundant in NIH3T3 ¢broblasts. Consistently, 13S E1a, a
viral activator of ATF-2, only activates transcription in
NIH3T3 cells. ATF-2 is synthesized as an inactive protein,
unable to bind DNA or activate transcription if tethered to
a promoter. Interaction with E1a enables ATF-2 to become
an active DNA-binding and transactivator factor. Insensitiv-
ity to 13S E1a activation in hepatic cells might be due to the
fact that speci¢cally in these cells, ATF-2 is engaged in an
activating interaction with the CCAAT-binding proteins
CP1 or NF-I. Instead, the oncogenic activity of CR1 and
CR2 domains, present in both splicing forms of E1a, causes
an important inhibition of the FN promoter, which is clearly
not mediated through the CRE-CCAAT sites. A similar e¡ect
was described in the rat FN promoter: E1a repression in-
volves GC-rich sequences downstream of 3150, but cell-spe-
ci¢city was not investigated [24,25].
In the case of NIH3T3, a clear CRE-dependent 13S E1a
activation is observed. This is likely to be mediated by ATF-2,
which would be in an inactive form readily available for 13S
E1a interaction.
Therefore, we are in the presence of dualistic responses of
the same promoter to the same regulator in two di¡erent cell
types.
4.5. Concluding remarks
Taken together, the results presented indicate that in hep-
atic cells, ATF-2 takes part of a composite factor, together
with CCAAT-binding proteins. In the absence of binding to
CCAAT, this composite factor is not able to interact with the
FN promoter and other CRE-binding factors take over, ex-
plaining the di¡erential sensitivity of the wt and CCccT-mu-
tated promoters to 2FTA co-transfection.
We have performed gel mobility shift experiments looking
for cell-speci¢c complexes that might correlate with the ob-
served transcriptional responses. Either with FN-CRE or FN-
CCAAT probes, the same gel shift patterns were observed
with Hep3B, HepG2 and NIH3T3 nuclear extracts (data not
shown), which are in turn similar to those observed with rat
liver nuclear extracts [16,9,10]. This is not surprising because
binding to short probes does not re£ect the complexity and
selectivity of protein-protein and protein-DNA interactions
occurring in long promoter strings. For example, hepatic-spe-
ci¢c occupation of the CRE-CCAAT region is readily seen in
DNAse I footprintings of a 220 bp promoter fragment, but
not in gel shifts with short oligonucleotides [9].
ATF-2 is neither a substrate nor a mediator of PKA acti-
vation [26] and we know that the liver CCAAT-interacting
factor is di¡erent from the ATF-2 homodimer ([10] and un-
published results). We therefore envision that, within the com-
posite factor, ATF-2 exists as an heterodimer with a PKA-
responsive ATF factor, like ATF-1 or CREB. The fact that in
Hep3B cells, mutCRE causes the same reduction in cAMP
activation as the CCccT mutant or the double mutant sup-
ports the concept that the CRE-CCAAT region is a composite
element, similar to the one described by Yamamoto and co-
workers [17] for the AP-1 and glucocorticoid response element
sites, which confer glucocorticoid responsiveness to the pro-
liferin gene promoter. Composite elements like the FN-CRE-
CCAAT do not only regulate transcription, but also partic-
ipate in the modulation of alternative splicing, as we have
shown in a recent report where disruption of both sites greatly
altered the pattern of exon selection in the downstream tran-
script [27].
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